QUEBEC CITY, QUEBEC--(Marketwire - April 16, 2008) - Medicago Inc. (TSX VENTURE: MDG) today announced that it has successfully completed the current Good Manufacturing Practices (“cGMP”) qualification of its manufacturing facility located in the Technology Park of Quebec City, Canada. cGMP rules and regulations governing the development, manufacturing and control of pharmaceutical products apply to all stages of production, from early development to marketed products. This qualification will allow Medicago to produce clinical grade materials of H5N1 Avian Influenza Virus-Like Particles (“VLP”) vaccine candidates and other influenza vaccines.
